This is an aggregated industry headline. Read the full story at Drug Channels →
The Hidden Cost of 340B for Employers and Health Plans
By Adam J. Fein, Ph.D.For years, the controversy surrounding the 340B Drug Pricing Program has centered on hospitals, manufacturers, and contract pharmacies. But employers and health plans have become major participants in the program's economics-even though many don't realize it. The short video be
By Drug Channels
· Jul 8, 2026
· via Drug Channels
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineDrug Channels
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
With increased sales of its newer drugs compensating for declining revenues from its multiple sclerosis portfo…
The WeekFierceBiotech ↗
Johnson & Johnson is cruising deeper into in vivo CAR-T waters, paying $785 million upfront to strike a de…
The WeekBriefing
CMS’s proposed 2027 OPPS rule would cut 340B drug reimbursement from ASP plus 6% to ASP minus 33.4%. The savin…